SGH
SAGE

Schonfeld Group Holdings’s Sage Therapeutics SAGE Stock Holding History

Schonfeld Group Holdings’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$286K Buy
+4,902
New +$243K 0.18% 169

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Schonfeld Group Holdings's SAGE Position: Q4 2015 in Review

Schonfeld Group Holdings opened a new position in Sage Therapeutics (SAGE) in Q4 2015: 4,902 shares worth $286K. The stake represents 0.18% of the portfolio and ranks #169 among its holdings.

137 funds tracked by Wall St. Rank hold SAGE as of Q4 2015.

  • Schonfeld Group Holdings held 4,902 shares of Sage Therapeutics worth $286K as of Q4 2015.
  • Sage Therapeutics was a new Schonfeld Group Holdings position in Q4 2015.
  • Sage Therapeutics made up 0.18% of Schonfeld Group Holdings's portfolio in Q4 2015, its #169 holding.
  • 137 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2015.

Based on Schonfeld Group Holdings's 13F filing for Q4 2015, filed 12 Feb 2016.